Shandong Lukang Pharmaceutical Co.,Ltd. (SHA:600789)
China · Delayed Price · Currency is CNY 7.79
+0.07 (0.91%)
Sep 10, 2026, 2:35 PM CST
SHA:600789 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 8,069 | 9,449 | 8,582 | 6,361 | 6,418 | 6,593 | |
Market Cap Growth | -9.40% | 10.09% | 34.92% | -0.89% | -2.66% | -20.06% |
Enterprise Value | 8,662 | 11,813 | 10,613 | 8,698 | 8,777 | 8,485 |
Last Close Price | 7.72 | 8.98 | 9.38 | 6.91 | 6.97 | 7.13 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 54.94 | 84.13 | 21.75 | 25.84 | 46.50 | 74.00 |
PS Ratio | 1.38 | 1.64 | 1.38 | 1.03 | 1.14 | 1.34 |
PB Ratio | 1.49 | 1.80 | 2.11 | 1.70 | 1.83 | 1.92 |
P/TBV Ratio | 1.81 | 2.18 | 2.72 | 2.20 | 2.33 | 2.43 |
P/FCF Ratio | 21.39 | 26.30 | 69.42 | 23.91 | 400.72 | - |
P/OCF Ratio | 10.84 | 13.53 | 21.31 | 10.53 | 14.44 | 37.15 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.48 | 2.05 | 1.70 | 1.42 | 1.56 | 1.72 |
EV/EBITDA Ratio | 13.66 | 18.92 | 14.78 | 13.44 | 16.19 | 18.82 |
EV/EBIT Ratio | 44.13 | 60.62 | 33.51 | 32.68 | 45.23 | 59.19 |
EV/FCF Ratio | 22.97 | 32.88 | 85.85 | 32.69 | 547.99 | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.43 | 0.58 | 0.70 | 0.77 | 0.81 | 0.77 |
Debt / EBITDA Ratio | 3.67 | 4.92 | 3.95 | 4.44 | 5.26 | 5.88 |
Debt / FCF Ratio | 6.17 | 8.54 | 22.97 | 10.81 | 178.17 | - |
Net Debt / Equity Ratio | 0.08 | 0.14 | 0.51 | 0.56 | 0.62 | 0.60 |
Net Debt / EBITDA Ratio | 0.70 | 1.16 | 2.88 | 3.21 | 3.99 | 4.59 |
Net Debt / FCF Ratio | 1.18 | 2.02 | 16.71 | 7.80 | 135.08 | -6.66 |
Asset Turnover | 0.62 | 0.60 | 0.70 | 0.70 | 0.68 | 0.65 |
Inventory Turnover | 3.59 | 3.32 | 3.33 | 3.25 | 3.29 | 3.64 |
Quick Ratio | 1.13 | 1.07 | 0.84 | 0.61 | 0.47 | 0.41 |
Current Ratio | 1.61 | 1.46 | 1.35 | 1.04 | 0.85 | 0.79 |
Return on Equity (ROE) | 3.10% | 2.40% | 10.47% | 7.08% | 4.13% | 2.65% |
Return on Assets (ROA) | 1.31% | 1.27% | 2.21% | 1.90% | 1.47% | 1.19% |
Return on Invested Capital (ROIC) | 2.84% | 2.23% | 4.99% | 4.36% | 3.31% | 2.18% |
Return on Capital Employed (ROCE) | 2.90% | 2.90% | 5.20% | 5.00% | 4.20% | 3.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 9, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 1.78% | 1.19% | 4.60% | 3.87% | 2.15% | 1.35% |
FCF Yield | 4.67% | 3.80% | 1.44% | 4.18% | 0.25% | -4.72% |
Dividend Yield | 0.66% | 0.56% | 1.41% | 1.30% | 0.72% | 0.70% |
Payout Ratio | 55.13% | 148.08% | 59.17% | 58.38% | 101.14% | 186.75% |
Buyback Yield / Dilution | -15.16% | -4.35% | -2.01% | 4.45% | -3.27% | 2.25% |
Total Shareholder Return | -14.50% | -3.79% | -0.60% | 5.75% | -2.55% | 2.95% |